• LAST PRICE
    3.5200
  • TODAY'S CHANGE (%)
    Trending Down-0.2100 (-5.6300%)
  • Bid / Lots
    2.2300/ 3
  • Ask / Lots
    3.5600/ 2
  • Open / Previous Close
    3.7300 / 3.7300
  • Day Range
    Low 3.5000
    High 3.7300
  • 52 Week Range
    Low 3.2105
    High 71.6000
  • Volume
    21,413
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.73
TimeVolumeKPRX
09:32 ET10353.73
10:09 ET5003.61
10:11 ET1003.6
10:13 ET31003.63
10:24 ET16003.58
10:27 ET2873.5301
10:31 ET1003.55
10:40 ET10003.55
10:54 ET4003.57
11:07 ET1003.57
11:23 ET2003.58
12:15 ET1003.59
12:55 ET27743.58
01:11 ET8263.531
01:18 ET2503.55
01:27 ET5503.5245
01:29 ET28663.5
02:03 ET6753.5
02:05 ET1003.5
02:32 ET1003.53
02:39 ET1003.54
02:54 ET1003.58
03:37 ET2253.5234
03:53 ET1003.52
03:55 ET3003.54
04:00 ET6153.52
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKPRX
Kiora Pharmaceuticals Inc
4.3M
-0.1x
---
United StatesPRFX
PainReform Ltd
4.3M
-0.6x
---
United StatesNXEN
Nexien Biopharma Inc
3.8M
-6.0x
---
United StatesMDCN
Medican Enterprises Inc
3.9M
0.0x
---
United StatesLRSV
Link Reservations Inc
3.6M
0.0x
---
United StatesHOTH
Hoth Therapeutics Inc
4.9M
-0.3x
---
As of 2022-12-06

Company Information

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Its wholly owned subsidiaries include Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH, Bayon Therapeutics, Inc. and Kiora Pharmaceuticals Pty Ltd.

Contact Information

Headquarters
1371 EAST 2100 SOUTH, SUITE 200SALT LAKE CITY, UT, United States 84105
Phone
781-788-8869
Fax
302-636-5454

Executives

Independent Chairman of the Board
Paul Chaney
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Brian Strem
Executive Vice President - Finance
Melissa Tosca
Chief Development Officer
Eric Daniels
Independent Director
Kenneth Gayron

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.3M
Revenue (TTM)
$0.00
Shares Outstanding
1.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.25
EPS
$-40.43
Book Value
$46.05
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.